Citius pharmaceuticals and citius oncology highlight lymphir commercial launch planned for the first half of 2025

Cranford, n.j. , jan. 7, 2025 /prnewswire/ -- citius pharmaceuticals, inc. ("citius pharma" or the "company") (nasdaq: ctxr) and its oncology-focused subsidiary, citius oncology (nasdaq: ctor), today announced significant progress in preparations for the commercial launch of lymphir™, an innovative immunotherapy for the treatment of adults with relapsed or refractory cutaneous t-cell lymphoma (ctcl).
CTXR Ratings Summary
CTXR Quant Ranking